AxoGen, Inc. (NASDAQ:AXGN) Given Consensus Rating of “Moderate Buy” by Analysts

AxoGen, Inc. (NASDAQ:AXGN) has been given an average rating of “Moderate Buy” by the eleven research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $51.00.

A number of equities analysts have recently issued reports on the company. HC Wainwright upped their price objective on AxoGen from $50.00 to $53.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Jefferies Financial Group reissued a “buy” rating and set a $55.00 price objective on shares of AxoGen in a report on Wednesday, July 29th. Canaccord Genuity Group upped their target price on AxoGen from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Citizens Jmp increased their price target on shares of AxoGen from $50.00 to $55.00 and gave the company a “market outperform” rating in a research report on Thursday, July 30th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $48.00 price target on shares of AxoGen in a research report on Wednesday, April 29th.

Insider Transactions at AxoGen

In related news, EVP Marc A. Began sold 67,500 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $47.34, for a total transaction of $3,195,450.00. Following the completion of the sale, the executive vice president directly owned 50,135 shares in the company, valued at $2,373,390.90. This represents a 57.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathy Johnson Weiler sold 14,150 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $45.30, for a total transaction of $640,995.00. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 95,003 shares of company stock worth $4,482,997. Insiders own 2.44% of the company’s stock.

Institutional Trading of AxoGen

Institutional investors have recently modified their holdings of the company. Lisanti Capital Growth LLC purchased a new stake in AxoGen in the 2nd quarter worth approximately $4,183,000. Stephens Investment Management Group LLC purchased a new position in shares of AxoGen during the fourth quarter valued at approximately $5,043,000. Edmond DE Rothschild Holding S.A. purchased a new position in shares of AxoGen during the second quarter valued at approximately $1,469,000. Legato Capital Management LLC bought a new position in shares of AxoGen during the fourth quarter valued at approximately $1,323,000. Finally, SummitTX Capital L.P. bought a new position in shares of AxoGen during the first quarter valued at approximately $7,769,000. 80.29% of the stock is currently owned by hedge funds and other institutional investors.

AxoGen Price Performance

Shares of AxoGen stock traded down $0.47 on Monday, hitting $49.93. 67,161 shares of the company traded hands, compared to its average volume of 1,099,636. The firm’s 50-day simple moving average is $44.11 and its 200 day simple moving average is $38.98. The company has a current ratio of 6.60, a quick ratio of 5.04 and a debt-to-equity ratio of 0.07. The company has a market cap of $2.68 billion, a P/E ratio of -73.43 and a beta of 1.11. AxoGen has a 12-month low of $13.64 and a 12-month high of $51.06.

AxoGen (NASDAQ:AXGN) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.12. The company had revenue of $69.73 million during the quarter, compared to analyst estimates of $67.10 million. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. Analysts expect that AxoGen will post -0.45 earnings per share for the current fiscal year.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.